IDEAYA Biosciences (IDYA) Stock Analysis & AI Equity Report
IDEAYA Biosciences (IDYA) overview
IDEAYA Biosciences (IDYA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 219m and operating profit of USD -159m; the year-end share price was 34.57 USD and market capitalisation was USD 3,035m. IDEAYA Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get IDEAYA Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About IDEAYA Biosciences
IDEAYA Biosciences discovers and develops precision medicines for genetically defined cancers. Its darovasertib and crizotinib combination has an NDA submitted for metastatic uveal melanoma, while the company also studies darovasertib in primary disease. IDEAYA is advancing other oncology programs, including IDE849, a DLL3-targeting TOP1 antibody-drug conjugate in Phase 1/2 development for small-cell lung cancer and neuroendocrine carcinomas.
Generate the IDEAYA Biosciences report
IDEAYA Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for IDEAYA Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on IDEAYA Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.